This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n7http://linked.opendata.cz/resource/drugbank/mixture/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00093/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00093/identifier/pharmgkb/
n4http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00093/identifier/drugbank/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/drugbank/
n14http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00093
rdf:type
n5:Drug
n5:description
A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two cysteine residues. Its antidiuretic effects are less than those of vasopressin. It is used as a vasoconstrictor in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth. [ChEBI]
n5:generalReferences
# Cecanho R, De Luca LA Jr, Ranali J: Cardiovascular effects of felypressin. Anesth Prog. 2006 Winter;53(4):119-25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17177590
n5:group
approved
n5:indication
For use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential.
n5:manufacturer
n8:271B44B8-363D-11E5-9242-09173F13E4C5
owl:sameAs
n4:DB00093 n12:DB00093
dcterms:title
Felypressin
adms:identifier
n11:PA164744374 n13:Felypressin n16:DB00093
n5:mechanismOfAction
Felypressin binds to the vasopressin receptor V1a. This causes contraction of the smooth muscle in the vascular bed, especially capillaries, small arterioles and venules.
n5:synonym
PLV-2 2-(L-phenylalanine)-8-L-lysinevasopressin Felypressinum Felypressin Felypressine Felipresina
n5:mixture
n7:271B44B4-363D-11E5-9242-09173F13E4C5 n7:271B44B5-363D-11E5-9242-09173F13E4C5 n7:271B44B6-363D-11E5-9242-09173F13E4C5 n7:271B44B7-363D-11E5-9242-09173F13E4C5
n5:synthesisReference
Boissonnas, R.and Guttmann, S.; U.S. Patent 3,232,923; February 1, 1966: assigned to Sandoz AG, Switzerland.
n14:hasConcept
n15:M0008307
n5:IUPAC-Name
n6:271B44BD-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B44C3-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B44C2-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B44BF-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B44C0-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B44C1-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B44BB-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B44B9-363D-11E5-9242-09173F13E4C5 n6:271B44BC-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B44BA-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B44C9-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B44CA-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B44C4-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B44C5-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B44C7-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B44C6-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B44C8-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
56-59-7
n5:category
n5:Bioavailability
n6:271B44CF-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B44D1-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B44D2-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B44D3-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B44CE-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B44CD-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B44D0-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B44BE-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B44CB-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B44CC-363D-11E5-9242-09173F13E4C5